“Grindeks” was proposed by the pharmaceutical company “Instituto Biológico Argentino S.A.I.C.” (“BIOL”) for a joint international project “Oxytocin in Uniject” conducted by PATH*. Within the scope of the project “Grindeks” will produce and supply an active pharmaceutical ingredient oxytocin to “BIOL”. “Oxytocin in Uniject” is an innovative non-reusable injection device prefilled with a single dose of oxytocin. “PATH” and “BIOL” have collaborated since 2004 to make oxytocin available in “Uniject” as part of numerous global initiatives to reduce materially the postpartum hemorrhage in women**, in general, in the developing countries. “PATH” developed the “Uniject” device to improve the ease and safety of administration of injectable drugs. “BIOL” in cooperation with “PATH” conducted investigation, development and registration of the final product in “Uniject”. At the moment, the product is already registered in Argentina; soon its registration will be launched in other countries of Latin America, later in other world countries. To continue established cooperation “BIOL” and the “World Health Organisation” (“WHO”) invited “Grindeks” to take part in “WHO”'s work to update its process for qualifying pharmaceutical suppliers. The invitation was based on the international partners' positive references as to high quality of oxytocin produced by “Grindeks”, which is also proved by registration of the product in such quality standard demanding country as the US as well as Australia, EU and other countries. In the course of the project “Grindeks” developed the monograph about oxytocin quality, which “WHO” will apply in assessment of the product's quality in future projects. Andris Jegorovs, Director of “Grindeks” API Business Unit emphasises: “Invitation to cooperate in these global projects is the highest assessment of our APIs quality and professional accomplishment in the development of monograph. This will ensure an opportunity for “Grindeks” to become the largest manufacturer of oxytocin substance in the world.” “Grindeks” is carrying out API business development successfully both on existing and new markets, whereupon the export of APIs in 2008 reached 5.1million lats, which is by 1.2 million lats or 30.8 % more than in 2007. Oxytocin is one of the most demanded “Grindeks” APIs. Exporting it, “Grindeks” has gained 35% of the world market. Market position strengthening and footholds gaining in new markets are being advantaged by international certificates proving the quality of oxytocin, such as “Good Manufacturing Practice”, “Certificate of Suitability” which is facilitating registration of the product in any and all countries where Europe pharmacopoeia is applicable, as well as “Food and Drug Administration” conclusion affirming conformity with USA quality standards. About “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main business fields are research, development and manufacturing of brand products, generics and APIs. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as ten representative offices. Products of the company are exported to more than 40 countries. Main markets are the Baltic States, Russia and CIS countries, Japan, USA. “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. You are kindly invited to www.grindeks.lv to get to know more about our company! About “BIOL” Founded in 1908, “BIOL” is private and medium-sized argentine company, specialized in the elaboration of biological products. Nowadays “BIOL” produces and commercializes products of its own elaboration and from licences of prestigious foreign companies, being its main goal to contribute to improve the patients' quality of life by providing efficient and reliable medications. “BIOL” counts on a wide range of products orientated to different medicinal specialties, such as Gynaecology and Obstetrics, Critical Care and Biological Line (Sera and Vaccines). Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phones: +371 67083370, +371 29256012 E-mail: laila.klavina@grindeks.lv * PATH - Program for Appropriate Technology in Health - is an international nonprofit organisation, which in co-operation with different state and private sector partners provides appropriate health technologies and vital strategies, mainly, to developing countries and poor region. More detailed information: www.path.org and www.pphprevention.org **According to WHO's data, postpartum haemorrhage, or excessive bleeding after childbirth, kills an estimated 150,000 women each year